During this support group meeting we will be joined by Rebekah Tobin of Takeda Oncology. She will provide us with information regarding risks of multiple myeloma including:

• Explains why understanding risk status is important
— The difference between low- and high-risk categories
— How risk status is assessed
— The difference between risk factors and risk status
• Details the factors that contribute to risk status, including patient-related characteristics, tumor
burden and the genetic features of cancer cells
• Describes chromosomes and their role in multiple myeloma in a patient-friendly, visual way,
including explanations of chromosomal abnormalities, such as translocations, gains, and deletions
• Lists chromosomal abnormalities commonly associated with multiple myeloma
• Explains the importance of the fluorescence in situ hybridization (FISH) test and other
chromosomal tests
• Offers questions listeners can consider posing to their healthcare team

Attendance can be in person (Lower Level Meeting Room B) or via Zoom.

For more information, please contact Shirley Jonas 701-527-6529 or Marcus Roehrich 701-333-8191 or via  email: [email protected]